Buchumschlag

Persistence of Symptoms of Anxiety and Depression in Inflammatory Bowel Disease: A Longitudinal Follow‐Up Study

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Christy Riggott, Keeley M. Fairbrass, Elspeth A. Guthrie, Christopher J. Black, Christian P. Selinger, Alexander C. Ford, David J. Gracie
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Prevalence and Predictors of Symptoms of Anxiety or Depression at Diagnosis in Patients With Inflammatory Bowel Disease: An Inception Cohort
von: Christy Riggott, et al.
Veröffentlicht: (2025)

Editorial: The Devil Is in the Detail—Interpreting the Findings of Network Meta‐Analyses
von: Christy Riggott, et al.
Veröffentlicht: (2025)

Review article: The role of the gut–brain axis in inflammatory bowel disease and its therapeutic implications
von: Christy Riggott, et al.
Veröffentlicht: (2024)

Validating Simple Modifications to the Rome IV Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care
von: Vivek C. Goodoory, et al.
Veröffentlicht: (2024)

Letter: The Persistence of Anxiety and Depression in Inflammatory Bowel Disease: A Core Phenotype Beyond Inflammatory Activity
von: Brigida Barberio, et al.
Veröffentlicht: (2026)

Novel Symptom Subgroups in Patients With Irritable Bowel Syndrome Are Associated With Healthcare Utilisation in Secondary and Tertiary Care
von: Vivek C. Goodoory, et al.
Veröffentlicht: (2026)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
von: Isabel Carbery, et al.
Veröffentlicht: (2024)

Meta‐Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy
von: Shamim Joudaki, et al.
Veröffentlicht: (2025)

Editorial: Cumulative Impact of Clinical Disease Activity, Biochemical Activity and Psychological Health on the Natural History of Inflammatory Bowel Disease During 8 Years of Longitudinal Follow‐Up
von: Ben Massouridis, et al.
Veröffentlicht: (2025)

Frailty Is Associated With All‐Cause and Acute Hospitalisations During 18 Months Follow‐Up in Older Patients With Inflammatory Bowel Disease
von: Anne B. Fons, et al.
Veröffentlicht: (2026)

Stability of Classification Systems for Irritable Bowel Syndrome
von: Mais Khasawneh, et al.
Veröffentlicht: (2025)

Meta‐Analysis: Improvement of Bowel Urgency With Advanced Therapies for Inflammatory Bowel Disease
von: Purab Patel, et al.
Veröffentlicht: (2025)

Meta‐Analysis: Prevalence of Eating Disorders in Inflammatory Bowel Disease
von: Quinn Goddard, et al.
Veröffentlicht: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease
von: Jeli Mendoza, et al.
Veröffentlicht: (2024)

Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation
von: Simone Chin, et al.
Veröffentlicht: (2025)

Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
von: Uma Mahadevan, et al.
Veröffentlicht: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease?
von: Matthew D. Coates, et al.
Veröffentlicht: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease
von: Marco Vincenzo Lenti, et al.
Veröffentlicht: (2025)

Systematic Review: Stigma Associated With Inflammatory Bowel Disease
von: Suprabhat Giri, et al.
Veröffentlicht: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease?
von: Agnes Hiu Yan Ho, et al.
Veröffentlicht: (2025)

Overall and Comparative Risk of Shingles With Advanced Therapies in Patients With Inflammatory Bowel Diseases
von: Dhruv Ahuja, et al.
Veröffentlicht: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
von: Jianhui Zhao, et al.
Veröffentlicht: (2024)

Prevalence of Opioid Use and Associated Healthcare Outcomes in Rome IV Irritable Bowel Syndrome in the United Kingdom
von: Mohsin F. Butt, et al.
Veröffentlicht: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
von: Fai Fai Ho, et al.
Veröffentlicht: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues
von: Stephanie Gold, et al.
Veröffentlicht: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
von: Suprabhat Giri, et al.
Veröffentlicht: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
von: Bharati Kochar, et al.
Veröffentlicht: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease
von: Nicholas Clark, et al.
Veröffentlicht: (2025)

Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide
von: Lynna Chen, et al.
Veröffentlicht: (2025)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet?
von: Joyce Wing Yan Mak
Veröffentlicht: (2025)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply
von: A. B. Fons, et al.
Veröffentlicht: (2026)

Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease
von: Jessica D. Lee, et al.
Veröffentlicht: (2025)

Editorial: High‐Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer
von: Alexandra Hickey, et al.
Veröffentlicht: (2025)

Long‐Term Outcomes Following Withdrawal of Anti‐Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long‐Term Study of GETECCU
von: María José Casanova, et al.
Veröffentlicht: (2025)

Mild Endoscopic Disease Activity Is Associated With Adverse Outcomes Among Older Adults With Inflammatory Bowel Disease
von: Catherine Z. Tang, et al.
Veröffentlicht: (2025)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's Reply
von: Aurelien Amiot, et al.
Veröffentlicht: (2025)

Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply
von: A. B. Fons, et al.
Veröffentlicht: (2026)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
von: Jessica A. Fitzpatrick, et al.
Veröffentlicht: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
von: Cristina Rubín de Célix, et al.
Veröffentlicht: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease
von: Cong Dai, et al.
Veröffentlicht: (2024)